CA
NZ
UK
AU
IND
US
…
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 46.97M | -2.81M | 10.39M | 20.28M | 63.79M |
| Net income | 37.03M | 0.86M | 4.95M | 15.53M | 94.90M |
| Selling general administrative | 326.24M | 290.69M | 264.53M | 283.81M | 250.20M |
| Selling and marketing expenses | - | 3.83M | 5.22M | - | - |
| Gross profit | 425.51M | 366.30M | 326.66M | 345.87M | 353.86M |
| Reconciled depreciation | 26.94M | 17.03M | 21.19M | 18.03M | 16.68M |
| Ebit | 46.97M | -1.26M | 12.58M | 22.30M | 72.92M |
| Ebitda | 73.91M | 15.76M | 36.03M | 40.32M | 89.58M |
| Depreciation and amortization | 26.94M | 17.03M | 23.45M | 18.02M | 16.66M |
| Non operating income net other | - | - | - | -0.01M | -1.90M |
| Operating income | 55.87M | -1.28M | 12.53M | 22.30M | 72.92M |
| Other operating expenses | 507.16M | 483.33M | 420.62M | 428.59M | 395.14M |
| Interest expense | 2.28M | 1.54M | 2.19M | 2.01M | 7.24M |
| Tax provision | 9.94M | -3.67M | 7.94M | 4.75M | -31.12M |
| Interest income | 2.28M | - | - | - | - |
| Net interest income | 2.28M | -1.54M | -1.66M | -2.01M | -7.24M |
| Income tax expense | 9.94M | -3.67M | 5.45M | 4.75M | -31.12M |
| Total revenue | 563.03M | 482.04M | 433.14M | 450.89M | 468.06M |
| Total operating expenses | 369.64M | 367.58M | 314.13M | 323.57M | 280.94M |
| Cost of revenue | 137.52M | 115.74M | 106.48M | 105.02M | 114.20M |
| Total other income expense net | -8.90M | -1.52M | -2.13M | -2.02M | -9.13M |
| Net income from continuing ops | 37.03M | 0.86M | 13.00M | 15.53M | 94.90M |
| Net income applicable to common shares | - | - | - | 15.53M | 94.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M |
| Intangible assets | 9.14M | 12.47M | 15.87M | 20.79M | 25.67M |
| Other current assets | 21.43M | 14.29M | 10.45M | 5.09M | 4.97M |
| Total liab | 164.81M | 112.57M | 181.36M | 183.69M | 201.22M |
| Total stockholder equity | 433.92M | 385.32M | 278.66M | 265.67M | 242.03M |
| Deferred long term liab | - | - | - | - | 1.22M |
| Other current liab | 49.53M | 35.17M | 30.07M | 26.45M | 2.30M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 133.80M | 122.43M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -3.08M | -40.11M | -40.97M | -45.30M | -60.13M |
| Other liab | - | - | - | 1.12M | 1.56M |
| Good will | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M |
| Other assets | - | - | 0.00M | 31.53M | 33.53M |
| Cash | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M |
| Total current liabilities | 100.12M | 77.48M | 80.51M | 75.02M | 82.00M |
| Current deferred revenue | - | - | - | - | 35.72M |
| Net debt | 39.16M | -92.26M | 15.01M | 21.31M | 18.37M |
| Short term debt | 18.64M | 9.11M | 19.71M | 16.25M | 14.64M |
| Short long term debt | - | - | 5.49M | 4.54M | 2.66M |
| Short long term debt total | 132.84M | 43.31M | 119.35M | 123.79M | 132.30M |
| Other stockholder equity | 303.19M | 302.99M | 319.62M | 310.96M | 302.15M |
| Property plant equipment | - | - | - | 102.46M | 79.16M |
| Total current assets | 362.19M | 285.94M | 225.04M | 222.61M | 226.98M |
| Net tangible assets | - | - | - | 216.11M | 187.59M |
| Net receivables | 217.45M | 109.86M | 82.00M | 89.45M | 82.46M |
| Long term debt | - | - | 60.74M | 66.23M | 70.77M |
| Inventory | 29.63M | 26.22M | 28.25M | 24.78M | 25.02M |
| Accounts payable | 31.95M | 28.91M | 30.72M | 32.33M | 29.34M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -45.30M | -60.13M |
| Non currrent assets other | 9.20M | 5.00M | 5.99M | 1.52M | 1.54M |
| Non current assets total | 236.54M | 211.94M | 234.98M | 226.75M | 216.28M |
| Capital lease obligations | 82.14M | 43.31M | 53.12M | 53.02M | 58.88M |
| Long term debt total | - | - | - | 66.23M | 70.77M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -10.03M | -31.70M | -33.90M | -31.22M |
| Change to liabilities | - | - | - | -8.52M | 6.44M |
| Total cashflows from investing activities | -14.15M | -10.03M | -24.36M | -33.90M | -31.22M |
| Net borrowings | -1.17M | -67.64M | -5.17M | -2.81M | 2.24M |
| Total cash from financing activities | -17.36M | 27.64M | -5.50M | -2.20M | -1.04M |
| Change to operating activities | - | - | - | -19.16M | -3.60M |
| Net income | 37.03M | 0.86M | 4.95M | 15.53M | 94.90M |
| Change in cash | -41.82M | 31.81M | 1.05M | -11.24M | 29.72M |
| Begin period cash flow | 136.15M | 104.34M | 103.29M | 114.53M | 84.81M |
| End period cash flow | 94.33M | 136.15M | 104.34M | 103.29M | 114.53M |
| Total cash from operating activities | -10.31M | 14.21M | 30.92M | 24.86M | 61.98M |
| Issuance of capital stock | 0.00M | 120.69M | 0.00M | 0.00M | 0.00M |
| Depreciation | 26.94M | 17.03M | 23.45M | 18.03M | 16.68M |
| Dividends paid | 11.37M | 1.80M | - | - | - |
| Change to inventory | -17.91M | -6.20M | 6.58M | -9.41M | -9.30M |
| Change to account receivables | -115.80M | -31.80M | 5.54M | -8.77M | -30.23M |
| Sale purchase of stock | 0.00M | -25.48M | -0.33M | 2.07M | 2.20M |
| Other cashflows from financing activities | -16.35M | 122.56M | -0.33M | -1.26M | 64.15M |
| Change to netincome | - | - | - | 15.23M | -25.46M |
| Capital expenditures | 14.15M | 10.03M | 24.36M | 33.90M | 31.22M |
| Change receivables | - | - | - | -15.78M | -34.81M |
| Cash flows other operating | - | - | - | 17.07M | 19.48M |
| Cash and cash equivalents changes | - | - | - | -11.24M | 29.72M |
| Change in working capital | -132.38M | -48.89M | -18.07M | -34.08M | -39.29M |
| Stock based compensation | 13.30M | 10.58M | 9.00M | 6.55M | 3.86M |
| Other non cash items | 35.30M | 45.35M | 9.59M | 16.85M | 17.80M |
| Free cash flow | -24.46M | 4.18M | 6.55M | -9.04M | 30.76M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings Inc |
-0.04 5.48% |
0.77 | - | 12.67 | 0.41 | 1.30 | 0.78 | 10.68 |
| MKKGY Merck KGaA ADR |
-0.01 0.03% |
33.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
0.04 0.02% |
169.25 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.90 4.50% |
20.91 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
4.03 10.61% |
42.00 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Gary S. Gillheeney Sr. | Pres, CEO & Director | 1955 |
| Mr. David C. Francisco | Chief Financial Officer | 1966 |
| Mr. Patrick Bilbo | Chief Operating Officer | 1962 |
| Ms. Lori H. Freedman B.A., Esq., J.D. | VP & Gen. Counsel | 1967 |
| Mr. Kurt Matheson | VP of Marketing | NA |
| Mr. Thomas L. Pearl | VP of HR | NA |
| Dr. Zorina Pitkin | Sr. VP of Quality Systems | NA |
| Mr. Brian Grow | Chief Commercial Officer | 1976 |
| Mr. William R. Kolb CPA | Sec. | NA |
| Mr. Gary S. Gillheeney Sr. | President, CEO, Chair of the Board | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...